The United States Food and Drug Administration has issued a formal warning regarding Ozempic when paired with lot number NAR0074 and serial number 430834149057. The notice, provided by Health Day, emphasizes safety and public health concerns tied to this specific identifier.
On December 21, the FDA reported the seizure of thousands of counterfeit doses of the obesity and diabetes treatment Ozempic, produced by Novo Nordisk. The agency also cautioned that dangerous counterfeit products can still be available for purchase in the marketplace, underscoring the risk to patients, clinicians, and pharmacies alike.
Healthcare providers and pharmacists are urged not to sell or administer Ozempic injections bearing the lot NAR0074 and serial 430834149057. There is a genuine concern that the injection needle may not be sterile, which means the risk extends beyond the drug itself to the delivery device. Counterfeit products can carry significant safety hazards, making verification essential.
In the reported incidents, five individuals incurred injuries following the injection of counterfeit Ozempic. While the cases did not result in life-threatening outcomes, each patient experienced classic Ozempic-associated side effects. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain, and constipation. The pattern of these reactions aligns with known adverse effects of the medication, complicating early identification of counterfeit exposure.
Experts stress a cautious approach when sourcing Ozempic or any biologic therapy. Verifying the product’s lot number and serial code with official channels, purchasing through authorized pharmacies, and checking for packaging integrity are prudent steps. In the event of any suspicious product, it is important to contact healthcare providers promptly and report the incident to the appropriate regulatory bodies. Safe handling and consistent monitoring of patient responses remain essential components of pharmacovigilance in these scenarios.
Last, the report notes that researchers have previously explored quick avenues to support cognitive function. While the idea exists in the literature, it is crucial to distinguish between early, preliminary findings and clinically validated therapies. Patients and clinicians should rely on approved, evidence-based practices for brain health and always consult medical professionals before trying new approaches.